Taxane containing regimens for metastatic breast cancer.

The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging (2004) 1.33

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther (2015) 0.87

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? Ther Adv Med Oncol (2016) 0.81

Survival of de novo stage IV breast cancer patients over three decades. J Cancer Res Clin Oncol (2016) 0.75

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 1.97

Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96

Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet (2001) 1.74

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol (2005) 1.71

Cholesterol and total mortality: need for larger trials. BMJ (1992) 1.57

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation (2000) 1.51

Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev (2006) 1.45

Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev (2007) 1.44

Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Ann Intern Med (1994) 1.40

Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37

Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol (2005) 1.35

Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med (1998) 1.22

Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation (1998) 1.18

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther (2007) 1.18

A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer (2005) 1.15

Total parenteral nutrition and cancer clinical trials. Cancer (1986) 1.09

Ethnic differences in mortality from insulin-dependent diabetes mellitus among people less than 25 years of age. Pediatrics (1999) 1.06

Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2005) 1.05

Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2004) 1.02

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia (2010) 1.01

Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J Immunol (2001) 1.00

Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev (2005) 0.97

Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med (2000) 0.96

Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation (2000) 0.93

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer (2005) 0.93

More on mammography. Lancet (2000) 0.91

Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) (2008) 0.87

Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg (2002) 0.87

After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation (1993) 0.87

Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results. Photomed Laser Surg (2006) 0.86

Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. Circulation (1997) 0.84

The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol (1996) 0.83

A risk index for early node-negative breast cancer. Br J Surg (2006) 0.83

Chemotherapy for metastatic breast cancer--when is enough enough? Eur J Cancer (1997) 0.82

Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2004) 0.81

Post-cancer fatigue is not associated with immune activation or altered cytokine production. Ann Oncol (2012) 0.81

Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". Br J Urol (1990) 0.81

Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial. Lancet (2001) 0.80

Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2004) 0.80

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol (2012) 0.78

Retinopathy in malaria. P N G Med J (1982) 0.78

HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation. Int Immunol (1996) 0.77

Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein. J Virol (1994) 0.77

Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. Br J Cancer (2012) 0.76

Safety of post-menopausal hormone replacement. Aust N Z J Med (1992) 0.75

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer (2015) 0.75

Winning the war on cancer. N Engl J Med (1997) 0.75

Single testing when two tests are available. Med Decis Making (1988) 0.75

Sociopsychological correlates of teen-age pregnancy in the United States Virgin Islands. Int J Ment Health (1993) 0.75

A catch-up phenomenon in skeletal development of children with Down's syndrome. J Ment Defic Res (1972) 0.75

Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital. Intern Med J (2014) 0.75